Danaher's Q2 Net Income Jumps 60% YoY, but Stock Plunges 11.74% on Q3 Guidance Concerns

As of 11:12 PM KST on the 21st, Danaher shares stood at $177.49 (about ₩262,863), down 11.74% from the previous close. The company's Q2 revenue, also reported that day, came in at $6.3 billion — above market expectations — but concerns over next quarter's revenue outlook weighed on the stock. Based on the SEC Form 8-K filing.

📊 Price at Time of Writing (July 21, 2026, 23:12 KST)
$177.49 ▼ -11.74%
≈ ₩262,863 (FX rate: 1,481)

Q2 Earnings at a Glance

Danaher's Q2 revenue rose 5.5% year-over-year to $6.3 billion. Net income surged 60% year-over-year to $870 million. Core revenue, which excludes the effects of acquisitions, divestitures, and currency, grew 3.0%, while core revenue excluding respiratory diagnostics sales rose 4.5%.

• Revenue: $6.3 billion, +5.5% YoY
• Earnings per share (EPS): $1.23, +60% YoY
• Adjusted (non-GAAP) EPS: $1.94, +8.0% YoY
• Operating cash flow: $1.5 billion
• Free cash flow (operating cash flow less capital expenditures): $1.3 billion

Outlook for Next Quarter

Danaher expects Q3 non-GAAP core revenue to grow 2.0% to 3.0% year-over-year. For the full year, the company forecasts core revenue growth of 3.0% to 4.0%. Danaher also raised its full-year adjusted EPS guidance to $8.45–$8.60, up from its earlier range of $8.35–$8.55. CEO Rainer Blair said, 'Our second-quarter results came in better than expected, and the acquisition of medical device maker Masimo also closed faster than anticipated.'

Market Reaction

Following the earnings release, Danaher shares plunged 11.74% to $177.49 (about ₩262,863). International media attributed the decline — despite net income and adjusted EPS beating expectations — to concerns over next quarter's revenue outlook and a slowdown in the life sciences equipment (bioprocessing) segment. Danaher said bioprocessing revenue was affected by delays in customer purchasing timelines, though it noted that bioprocessing orders grew in the mid-teens percentage range.

This article was automatically generated based on the original SEC Form 8-K filing and international media reports, with the goal of quickly relaying key data immediately after the announcement. Readers are advised to review the company's official filing before making trading decisions. Prices reflect the time this article was written and may differ from current levels.